On June 18, 2020, the Food and Drug Administration granted accelerated approval to tazemetostat (TAZVERIK™, Epizyme, Inc.), an EZH2 inhibitor, for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies,…
We are pleased to announce the assignment of a product-specific, permanent J-code for PADCEV. The Centers for Medicare & Medicaid Services (CMS) released the July 2020 Quarterly Healthcare Common Procedural Coding System (HCPCS) File, which includes the designation of J9177 for PADCEV with the effective date of July 1, 2020.1 * Note that the product’s NDC code…
On June 16, 2020, the Food and Drug Administration extended the indication of gemtuzumab ozogamicin (MYLOTARGTM, Wyeth Pharmaceuticals LLC) for newly-diagnosed CD33-positive acute myeloid leukemia (AML) to include pediatric patients 1 month and older. Efficacy and safety in the pediatric population were supported by data from AAML0531 (NCT00372593), a multicenter randomized study of 1,063 patients…
Food and Drug Administration granted accelerated approval to pembrolizumab (KEYTRUDA, Merck & Co., Inc.) for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment…
Gaucher disease is a lifelong, progressive disease. Test to know. It’s a simple blood test. Learn more!
Topic: Diagnosing aHUS – A Patient Case Journey – ICU Description: Louis Guzzi, MD, FCCM, Director of Critical Care, AdventHealth Waterman from Tavares, FL
Topic: aHUS: Disease & Diagnosis Transplant Case; Description: Craig Shadur, MD, FACP, Clinical Professor of Medicine, The University of Iowa from Iowa City, IA
Topic: aHUS Unbranded Disease and Diagnosis Core Bolted SLE Case; Description: Evan Leibowitz, MD, MS Rheumatologist- Chief of Rheumatology, The Valley Institute for Rheumatology and Autoimmune Diseases, Valley Medical Group from Ridgewood New Jersey
As our healthcare industry rapidly evolves to address the COVID-19 pandemic, new health policies and resources especially in the areas of patient affordability, care delivery and provider reimbursement continue to be released. That is why we have engaged Avalere, the health policy research firm, to develop and update a repository cataloging significant health policy changes….
Effective July 1, 2020, ENHERTU® (fam-trastuzumab deruxtecan-nxki) will have a permanent j-code: J9358. ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2–based regimens in the metastatic setting.1 This indication is approved under accelerated…
Genentech is excited to share the news of the new FDA approved indication. TECENTRIQ® (atezolizumab), in combination with bevacizumab, is indicated for the first-line (1L) treatment of unresectable or metastatic hepatocellular carcinoma (HCC) treatment. Please see attached for additional information, as well as the TECENTRIQ and the Avastin full Prescribing Information, and Important Safety Information for…
On June 15, 2020, the Food and Drug Administration granted accelerated approval to lurbinectedin (ZEPZELCA, Pharma Mar S.A.) for adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy. Efficacy was demonstrated in the PM1183-B-005-14 trial (Study B-005; NCT02454972), a multicenter open-label, multi-cohort study enrolling 105 patients with…
On May 29, 2020, the Food and Drug Administration approved ramucirumab (CYRAMZA®, Eli Lilly and Company) in combination with erlotinib for first-line treatment of metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations. Efficacy was evaluated in RELAY (NCT02411448), a multinational, randomized, double-blind, placebo-controlled,…
On May 29, 2020, the Food and Drug Administration approved atezolizumab in combination with bevacizumab (TECENTRIQ® and AVASTIN®, Genentech Inc.) for patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy. Efficacy was investigated in IMbrave150 (NCT03434379), a multicenter, international, open-label, randomized trial in patients with locally advanced unresectable or metastatic hepatocellular…
You are invited to a 1 hour webinar, Current and Emerging Trends in Multiple Myeloma, presented by Dr. David Vesole, Myeloma Division and Director, Myeloma Research at the John Theurer Cancer Center at Hackensack. Several different dates and time to choose from in June.
Due to COVID-19, the ASCO Direct™ Highlights meeting will be virtual. The 2020 ASCO Direct™ Highlights meeting will offer the same benefit that you have come to depend on. The abstracts chosen for presentation and discussion reflect the foremost research and strategies in oncology that directly impact patient care. Expert faculty will place abstract findings into clinical context and discuss how the results may change the current standard of care. Our conferencing platform allows for presentation, discussion, analysis, and attendee participation.
The FLASCO leadership is pleased to acknowledge Incyte Corporation as a FLASCO Diamond Corporate Member for 2020. Please welcome and THANK them for their support, when they call or e-mail you. Incyte is grounded in the rigorous pursuit of scientific excellence and driven to advance medical research to discover, develop and deliver novel medicines that…
RxVantage is offering an on-demand webinar on safely reopening amid COVID-19. Here is the link to the new on-demand webinar. This webinar covers policy recommendations for dealing with your rep/vendor community as well as recommendations for updating protocols to fit social distancing guidelines.
FLASCO is proud to announce the recipient of the 2020 Conquer Cancer -FLASCO Young Investigator Award Zaid H. Abdel Rahman, MD Mayo Clinic, Florida for his work “Evaluating the Impact of Philadelphia‐like Genetic Signature on Transplant Outcomes in Adults with B‐Lymphoblastic Leukemia/Lymphoma and Identification of Novel Fusion Partners” Dr. Zaid Abdel Rahman is an…
Virtual gathering delivers the latest cancer science to the global community Fort Myers, Fla., May 27, 2020 ——Florida Cancer Specialists & Research Institute (FCS) physicians are the co-authors of 20 research studies that will be presented at the American Society of Clinical Oncology (ASCO®) ASCO20 Virtual Scientific Program being held May 29 – 31, 2020. As the largest gathering…
On May 26, 2020, the Food and Drug Administration approved the combination of nivolumab (OPDIVO, Bristol-Myers Squibb Co.) plus ipilimumab (YERVOY, Bristol-Myers Squibb Co.) and 2 cycles of platinum-doublet chemotherapy as first-line treatment for patients with metastatic or recurrent non-small cell lung cancer (NSCLC), with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase…
On May 22, 2020, the Food and Drug Administration approved brigatinib (ALUNBRIG®, ARIAD Pharmaceuticals Inc.) for adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. Today, the FDA also approved the Vysis ALK Break Apart FISH Probe Kit (Abbott Molecular, Inc.) as a companion diagnostic…
On May 15, 2020, the Food and Drug Administration approved ripretinib (QINLOCK™, Deciphera Pharmaceuticals, LLC.), for adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib. Efficacy was evaluated in INVICTUS (NCT03353753), an international, multi-center, randomized (2:1), double-blind, placebo-controlled trial in 129 patients with…
On May 15, 2020, the Food and Drug Administration granted accelerated approval to rucaparib (RUBRACA®, Clovis Oncology, Inc.) for patients with deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. Efficacy was investigated in TRITON2 (NCT02952534), an ongoing, multi-center, single arm clinical trial…
On May 15, 2020, the Food and Drug Administration approved the combination of nivolumab (OPDIVO®, Bristol-Myers Squibb Co.) plus ipilimumab (YERVOY®, Bristol-Myers Squibb Co.) as first-line treatment for patients with metastatic non-small cell lung cancer whose tumors express PD-L1(≥1%), as determined by an FDA-approved test, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma…
From the American Society of Clinical Oncology in cooperation with the Food and Drug Administration (FDA) and as a service to our members, ASCO will periodically distribute information about newly approved therapies for cancer patients. This helps FDA inform oncologists and professionals in oncology-related fields about recent approvals in a timely manner. Included in the…
Cancer Patients Report High Satisfaction with Care During COVID-19 Pandemic Florida Cancer Specialists & Research Institute establishes protocols to protect patients with minimal disruption Fort Myers, Fla., May 19, 2020 —— Despite the many challenges of the current health care crisis, patients of Florida Cancer Specialists & Research Institute (FCS) report high satisfaction with the oncology provider’s response…
On May 19, 2020, the Food and Drug Administration approved olaparib (LYNPARZA®, AstraZeneca Pharmaceuticals, LP) for adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. Today, the FDA also approved FoundationOne® CDx (Foundation Medicine, Inc.)…
Takeda Oncology has changed the name of their patient support program from Takeda Oncology 1Point to Takeda Oncology Here2Assist™ effective May 18, 2020. Please note that only the name is changing. Patients and providers will continue to have the same high level of comprehensive, personalized support. Please review the attached information for important details.
On May 18, 2020, the Food and Drug Administration approved atezolizumab (TECENTRIQ®, Genentech Inc.) for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (PD-L1 stained ≥ 50% of tumor cells [TC ≥ 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 10% of…
On May 15, 2020, the Food and Drug Administration approved the combination of nivolumab (OPDIVO®, Bristol-Myers Squibb Co.) plus ipilimumab (YERVOY®, Bristol-Myers Squibb Co.) as first-line treatment for patients with metastatic non-small cell lung cancer whose tumors express PD-L1(≥1%), as determined by an FDA-approved test, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma…
Hello, At Genentech, we recognize that the COVID-19 national public health emergency is causing personal and financial challenges for many patients and their families. Getting their prescribed Genentech medicines shouldn’t be one of those challenges. Our highest priority is the health and safety of patients, and we believe it is critical for them to continue…
We invite you to learn more about: Current and emerging treatment options for Mantle Cell Lymphoma (MCL), Side-effect management and Ways to effectively communicate with your healthcare team about quality-of-life issues
On May 8, 2020, the Food and Drug Administration granted accelerated approval to selpercatinib (RETEVMOTM, Eli Lilly and Company) for the following indications: Adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC); Adult and pediatric patients ≥12 years of age with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy;…
Food and Drug Administration expanded the indication of olaparib (LYNPARZA®, AstraZeneca Pharmaceuticals, LP) to include its combination with bevacizumab for first-line maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination…
Drs. Mudad, Santos, Blanc and Jahanzeb of Florida Precision Oncology have opened their practice to Telehealth second opinions for your patients to avoid travel and receive expert advice from the comfort of their home while staying under your competent care. Contact 1-833-376-6265 (1-833-fponcol) for additional information. If your practice is offering services you would…
Good afternoon Bristol Myers Squibb Foundation Friends, Partners and Colleagues: We are excited to be sharing with you the launch of the COVID-19 Emergency Food Assistance Program, designed to keep immunocompromised patients safe during the COVID-19 Pandemic. This comprehensive program brings together the unique offerings of Team Rubicon, a nonprofit organization that serves communities by mobilizing veterans…
Join our Virtual Speaker Event to hear from EVENTYair Levy, MD, of Baylor Scott & White Health in Dallas, TX discuss 2020 ADCETRIS® (brentuximab vedotin)
Join our Virtual Speaker Event to hear from Andrew Evens, DO, MSc, of Rutgers Cancer Institute of New Jersey, New Brunswick, NJ discuss 2020 ADCETRIS® (brentuximab vedotin)
Join our Virtual Speaker Event to hear from Yair Levy, MD, of Baylor Scott & White Health in Dallas, TX discuss 2020 ADCETRIS® (brentuximab vedotin)
Join our Virtual Speaker Event to hear from Andrew Evens, DO, MSc, of Rutgers Cancer Institute of New Jersey, New Brunswick, NJ discuss 2020 ADCETRIS® (brentuximab vedotin)
On May 6, 2020, the Food and Drug Administration granted accelerated approval to capmatinib (TABRECTATM, Novartis) for adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test. Today, FDA also approved the FoundationOne CDx assay (Foundation…
Bayer today announced the launch of Test4TRKTM program in collaboration with NeoGenomics, Inc. to offer genomic cancer testing for NTRK gene fusions at no cost for patients with RAI-refractory (RAI-R) differentiated thyroid carcinoma (DTC) and metastatic colorectal cancer (mCRC) with high microsatellite instability (MSI-H). NTRK gene fusions, which have been shown to drive tumor growth, are more commonly found in patients with MSI-H mCRC and RAI-R DTC and may play a role in disease management.
Pfizer Inc.and BioNTech SE has announced that the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for the BNT162 vaccine program to prevent COVID-19. The trial is part of a global development program, and the dosing of the first cohort in Germany was completed last week. The Phase 1/2…
Fort Myers, Fla., May 6, 2020 — Florida Cancer Specialists & Research Institute (FCS) offers an advanced radiation therapy option for several types of cancers, which can lead to faster and shorter rounds of radiation therapy for patients. Hypofractionated radiation is a treatment technique where the total dose of radiation is delivered in fewer treatment sessions and results…
On May 1, 2020, the Food and Drug Administration approved daratumumab and hyaluronidase-fihj (DARZALEX FASPROTM, Janssen Biotech, Inc.) for adult patients with newly diagnosed or relapsed/refractory multiple myeloma. This new product allows for subcutaneous dosing of daratumumab. Daratumumab and hyaluronidase-fihj is approved for the following indications that intravenous daratumumab had previously received: in combination with…
Janssen, a Johnson and Johnson pharmaceutical company, is happy to share some exciting news – The FDA just approved DARZALEX FASPRO, a new subcutaneous formulation approved in four regimens across five indications, including newly diagnosed, transplant-ineligible and relapsed or refractory multiple myeloma. As you may know, today’s news is based on results from the COLUMBA…
In response to COVID-19, RxVantage adds Virtual Meetings to connect healthcare providers to life science experts RxVantage, the digital education platform that makes it easy for practices to engage with life science companies, today announced the launch of RxVantage Virtual Meetings, a hassle-free digital solution designed to help providers reconnect with life science experts…
The NCCN recently published the “Short-Term Recommendations for Non-Small Cell Lung Cancer Management During the COVID-19 Pandemic” and a recent piece was published in JNCCN. These updates recommend the use of circulating tumor DNA (ctDNA) testing, like Guardant360, for patients progressing on oral therapy rather than having a patient in the hospital for a tissue biopsy. …
Medical Oncologist/Hematologist joins FCS in Central Florida Fort Myers, Fla., May 4, 2020 — Florida Cancer Specialists & Research Institute (FCS) is pleased to welcome Medical Oncologist Martin F. Dietrich, MD, PhD. He is serving patients at the FCS Lake Mary Cancer Center at 805 Currency Circle, Lake Mary, FL and at 2572 W SR 426, Suite 3080,…
On April 29, 2020, the Food and Drug Administration approved niraparib (ZEJULA, GlaxoSmithKline) for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy. Efficacy was investigated in PRIMA (NCT02655016), a double-blind, placebo-controlled trial that randomized 733…
From the American Society of Clinical Oncology in cooperation with the Food and Drug Administration (FDA) and as a service to our members, ASCO will periodically distribute information about newly approved therapies for cancer patients. This helps FDA inform oncologists and professionals in oncology-related fields about recent approvals in a timely manner. Included in the…
In response to the COVID-19 pandemic, our healthcare system has had multiple policy changes, offering some flexibility to meet the needs of new patients and for those needing continuity in care. One of these changes includes access and coverage of telehealth during the current public health emergency. The attached resource from the Center for Connected Health Policy https://www.cchpca.org may…
Blood cancers are complex and multifaceted diseases, requiring knowledge by healthcare professionals on the array of diagnostic tests, treatment therapies, and survivorship issues. The LLS Podcast Series for Professionals provides up to date and accurate information on diagnosis, treatment and survivorship to educate HCPs treating patients with blood cancer. Listen in as we speak with experts…
On April 17, 2020, the Food and Drug Administration granted accelerated approval to pemigatinib (PEMAZYRE™, Incyte Corporation) for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. The FDA also approved the FoundationOne® CDX…
Merck Sharp & Dohme Corp. (“Merck”), a subsidiary of Merck & Co., Inc., is pleased to announce that ONTRUZANT® (trastuzumab-dttb) for injection, for intravenous use 21 mg/mL, a biosimilar* to Herceptin® (trastuzumab), is available through specialty distributors and wholesalers. Please contact your specialty distributor or wholesaler to confirm product availability. * Biosimilar means that the biological product is approved…
On April 22, 2020, the Food and Drug Administration granted accelerated approval to sacituzumab govitecan-hziy (TRODELVYTM, Immunomedics, Inc.) for adult patients with metastatic triple-negative breast cancer who received at least two prior therapies for metastatic disease. Efficacy was demonstrated in IMMU-132-01(NCT 01631552), a multicenter, single-arm, trial enrolling 108 patients with metastatic triple negative breast cancer…
On April 21, 2020, the Food and Drug Administration expanded the indication of ibrutinib (IMBRUVICA®, Pharmacyclics LLC) to include its combination with rituximab for the initial treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This review was conducted under Project Orbis, an initiative of the FDA Oncology Center of Excellence….
Register for a Live Webcast scheduled for Thursday, April 30, 2020 (several times available)! Featuring key insights from Joseph Mikhael, MD and Kenneth Shain, MD, PhD on relapsed and refractory multiple myeloma, OncLive®’s new broadcast will provide you with updates regarding management with SARCLISA. CLICK HERE Shared by Sanofi Genzyme.
We are excited to announce the approval of TUKYSA by the U.S. Food and Drug Administration (FDA). TUKYSA is indicated in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the…
On March 27, 2020, Congress enacted the Coronavirus Aid, Relief, and Economic Security (CARES) Act, which makes a number of changes to support the ability of the health care system to respond to the COVID-19 crisis. The CARES Act also includes additional appropriations for the U.S. Department of Health and Human Services (HHS), much of which will be distributed to providers.
At Johnson & Johnson we are uniting our resources and resolve to make headway against the COVID-19 pandemic. We’re excited to share this story through The Road to a Vaccine, an educational LIVE video series that profiles the global scientific collaborative work underway to develop a potential vaccine. The new series launches this upcoming…
In response to the COVID-19 pandemic, National Comprehensive Cancer Network® (NCCN®) has released recommendations for the use of hematopoietic growth factors during this time. The recommendations have been posted on NCCN’s website, along with other COVID-19 Resources: Hematopoietic Growth Factors Recommendations NCCN COVID-19 Resources NCCN noted that for acute myeloid leukemia (AML) and myelodysplastic syndromes…
Food and Drug Administration approved mitomycin (JELMYTO™, UroGen Pharma) for adult patients with low-grade upper tract urothelial cancer (LG-UTUC). More Information. April 15, 2020 https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-mitomycin-low-grade-upper-tract-urothelial-cancer Hematology/Oncology (Cancer) Approvals & Safety Notifications https://www.fda.gov/drugs/resources-information-approved-drugs/hematologyoncology-cancer-approvals-safety-notifications
Help for some of the Floridian patients who have newly diagnosed cancer or progressing cancer right now. Guardant Health COVID-19 Services Blank Requisition Form
From the American Society of Clinical Oncology in cooperation with the Food and Drug Administration (FDA) and as a service to our members, ASCO will periodically distribute information about newly approved therapies for cancer patients. This helps FDA inform oncologists and professionals in oncology-related fields about recent approvals in a timely manner. Included in the…
FDA does not issue approval announcements for every approval or drug label update that occurs in oncology and hematology. Please refer to Drugs@FDA for the latest approvals and prescribing information for specific products. 2020 Food and Drug Administration approved encorafenib (BRAFTOVI, Array BioPharma Inc.) in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer…
On April 8, 2020, the Food and Drug Administration approved encorafenib (BRAFTOVI, Array BioPharma Inc.) in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, detected by an FDA-approved test, after prior therapy. Efficacy was evaluated in a randomized, active-controlled, open-label, multicenter trial (BEACON CRC;…
The FDA approval marks the second indication for Reblozyl and the first new treatment option in over a decade for patients with MDS who require red blood cell (RBC) transfusions and have failed an erythropoiesis stimulating agent Reblozyl regulates late-stage RBC maturation to relieve patients from the burden of regular RBC transfusions PRINCETON, N.J. &…
We are committed to providing support to patients who need our medicines. The COVID-19 pandemic has created unprecedented financial challenges for patients and families. As more patients face difficult decisions in their daily lives, it is important to continue their treatments. We are proud to offer relief through our existing Bristol Myers Squibb patient support…
PRINCETON, N.J. – April 7, 2020 – Bristol Myers Squibb (NYSE: BMY) today announced an expansion of its existing patient support programs to help eligible unemployed patients in the U.S. who have lost their health insurance due to the COVID-19 pandemic. The expanded program offers access to any branded Bristol Myers Squibb medicine for free,…
Food and Drug Administration approved luspatercept-aamt (REBLOZYL, Celgene Corporation) for the treatment of anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell (RBC) units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis…
From the American Society of Clinical Oncology in cooperation with the Food and Drug Administration (FDA) and as a service to our members, ASCO will periodically distribute information about newly approved therapies for cancer patients. This helps FDA inform oncologists and professionals in oncology-related fields about recent approvals in a timely manner. Included in the…
We invite you to learn more about:
aggressive non-Hodgkin lymphomas (NHL), treatments advances for aggressive lymphomas, Side-effects management and the value of open communication with your treatment team
Sandoz will be hosting a webinar March 25th at 11am ET with a Professor/Hospital Director from Italy to facilitate sharing of knowledge and clinical experience regarding the COVID-19 pandemic. Details are listed below. .
Dear Colleagues: Please take three minutes of your time to answer these important questions: https://www.surveymonkey.com/r/C8ZDYNW about the impact of the current COVID-19 pandemic on our practices, needs, and available resources. This survey has been prepared by the multi-state and international cardio-oncology collaborative network from the American College of Cardiology (ACC), American Society of Clinical Oncology (ASCO) and…
Great news! Puma Biotechnology received U.S. FDA approval for Neratinib to Treat HER2-Positive Metastatic Breast Cancer. The sNDA approval was based on results of the Phase III NALA trial, a randomized controlled trial of neratinib plus capecitabine in patients with HER2-positive metastatic breast cancer who have received two or more prior anti-HER2-based regimens. Adam M….
Novartis today announced a broad set of measures to support the global response to the COVID-19 pandemic. These measures include the creation of a global fund to support communities around the world impacted by the COVID-19 pandemic as well as the company’s decision to join two key cross-industry R&D initiatives. For more information click here.
© 2021 FLASCO | Premium Website Design by The HDG
